Cardiovascular drug therapy and surrogate COVID-19 outcomes: which is the impact of the “miraculous” sodium-glucose co-transporter-2 inhibitors?

Effects of long-term use of sodium-glucose co-transporter-2 inhibitors on plasma volume status in patients with type 2 diabetes mellitus: Sub-analysis of a prospective, observational study during the COVID-19 pandemic

“…Improvement in myocardial energetics, reduction of cardiomyocyte apoptosis, and attenuation of sympathetic nervous system activity have also been proposed [6]. Some of these effects might also be valuable against COVID-19, which can prioritize the use of SGLT-2 inhibitors in subjects with T2DM during this hazardous pandemic [15]. Whether SGLT-2 inhibitors modify fluid volume regulation in the long term has to be clarified in future trials.…”